GSK says its drug for chron­ic hep B could ‘lead to a func­tion­al cure’ — but will it be alone or in com­bi­na­tion?

GSK, new­ly brand­ed and soon-to-be de­merged, shared in­ter­im re­sults from its Phase II tri­al on its chron­ic he­pati­tis B treat­ment, one that it says has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.